EGFR and central nervous system cancer: Recent studies and advancements in technologies like molecular profiling have significantly contributed to our understanding of gliomagenesis, indicating correlations between tumor location, molecular subtypes, and clinical outcomes.7–10 For instance, Tejada Neyra et al. demonstrated that IDH-mutated gliomas tend to cluster around the rostral extension of the lateral ventricles using a voxel-based lesion-symptom mapping.7 Additionally, Ellingson et al. found that EGFR-amplified and EGFR variant 3-expressing tumors predominantly occurred in the left temporal lobe.